Zimberelimab

Generic Name
Zimberelimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2259860-24-5
Unique Ingredient Identifier
ZBL7O904IL
Indication

用于治疗二线以上复发或难治性经典型霍奇金淋巴瘤(r/r cHL)患者。

Associated Conditions
-
Associated Therapies
-

Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2021-08-16
Last Posted Date
2024-12-20
Lead Sponsor
Gilead Sciences
Target Recruit Count
376
Registration Number
NCT05007782
Locations
🇺🇸

University of California San Diego, La Jolla, California, United States

🇺🇸

Stanford Cancer Center, Palo Alto, California, United States

🇺🇸

Smilow Cancer Center, New Haven, Connecticut, United States

and more 22 locations

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

First Posted Date
2021-04-22
Last Posted Date
2024-10-15
Lead Sponsor
Gilead Sciences
Target Recruit Count
193
Registration Number
NCT04854499
Locations
🇺🇸

UCLA Hematology/Oncology, Los Angeles, California, United States

🇺🇸

Memorial Healthcare System, Hollywood, Florida, United States

🇧🇪

Algemeen Ziekenhuis Klina, Brasschaat, Belgium

and more 84 locations

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

First Posted Date
2021-03-10
Last Posted Date
2024-04-09
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
30
Registration Number
NCT04791839
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

First Posted Date
2021-02-26
Last Posted Date
2024-12-18
Lead Sponsor
Arcus Biosciences, Inc.
Target Recruit Count
94
Registration Number
NCT04772989
Locations
🇺🇸

University of Wisconsin - Madison, Madison, Wisconsin, United States

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Virginia Cancer Specialists, Fairfax, Virginia, United States

and more 19 locations

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors

First Posted Date
2021-02-10
Last Posted Date
2022-12-05
Lead Sponsor
Gilead Sciences
Target Recruit Count
13
Registration Number
NCT04747470
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

🇺🇸

NEXT oncology, San Antonio, Texas, United States

🇺🇸

START Midwest, Grand Rapids, Michigan, United States

and more 1 locations

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

First Posted Date
2021-02-03
Last Posted Date
2024-12-12
Lead Sponsor
Arcus Biosciences, Inc.
Target Recruit Count
169
Registration Number
NCT04736173
Locations
🇺🇸

City of Hope-Duarte, Duarte, California, United States

🇺🇸

City of Hope - Huntington Beach (Including Long Beach Elm), Huntington Beach, California, United States

🇺🇸

City Of Hope, Irvine, California, United States

and more 108 locations

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

First Posted Date
2020-12-09
Last Posted Date
2024-12-20
Lead Sponsor
Arcus Biosciences, Inc.
Target Recruit Count
227
Registration Number
NCT04660812
Locations
🇮🇹

Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica, Firenze, Italy

🇮🇹

Azienda Ospedaliera Niguarda Ca' Granda, Milano, Italy

🇮🇹

Instituto Europeo di Oncologia, Milano, Italy

and more 46 locations

AB154 Combined with AB122 for Recurrent Glioblastoma

Early Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2020-12-07
Last Posted Date
2024-12-17
Lead Sponsor
Yale University
Target Recruit Count
46
Registration Number
NCT04656535
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

🇺🇸

Yale University, New Haven, Connecticut, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

First Posted Date
2020-05-11
Last Posted Date
2024-06-03
Lead Sponsor
Arcus Biosciences, Inc.
Target Recruit Count
173
Registration Number
NCT04381832
Locations
🇺🇸

Florida Cancer Specialists East, West Palm Beach, Florida, United States

🇺🇸

The Oncology Institute of Hope & Innovation, Cerritos, California, United States

🇺🇸

The University of California, Los Angeles, Encino, California, United States

and more 16 locations
© Copyright 2024. All Rights Reserved by MedPath